# Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

> **NCT03003962** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 669 (actual)

## Conditions studied

- Non Small Cell Lung Carcinoma NSCLC

## Interventions

- **DRUG:** Durvalumab (MEDI4736)
- **DRUG:** Paclitaxel + carboplatin
- **DRUG:** Gemcitabine + cisplatin
- **DRUG:** Gemcitabine + carboplatin
- **DRUG:** Pemetrexed + cisplatin
- **DRUG:** Pemetrexed + carboplatin

## Key facts

- **NCT ID:** NCT03003962
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-01-02
- **Primary completion:** 2022-10-27
- **Final completion:** 2026-06-30
- **Target enrollment:** 669 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03003962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03003962, "Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03003962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*